Vertex Pharmaceuticals (VRTX) Accumulated Expenses (2009 - 2026)

Vertex Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $3.0 billion for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 1.1% year-over-year to $3.0 billion; the TTM figure through Mar 2026 stood at $3.0 billion (up 1.1% YoY), while the FY2025 annual figure was $3.0 billion, up 6.55% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.0 billion, roughly flat from $3.0 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $3.6 billion in Q3 2025, with the low at $1.7 billion in Q1 2022.
• The 5-year median for Accumulated Expenses is $2.8 billion (2024), against an average of $2.7 billion.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses surged 42.96% in 2022, then grew 1.1% in 2026.
• Vertex Pharmaceuticals' Accumulated Expenses stood at $2.1 billion in 2022, then gained by 24.86% to $2.7 billion in 2023, then climbed by 5.02% to $2.8 billion in 2024, then gained by 6.55% to $3.0 billion in 2025, then increased by 0.44% to $3.0 billion in 2026.
• Business Quant data shows VRTX's Accumulated Expenses at $3.0 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.6 billion in Q3 2025.